Expected revenue slump spurs Lilly to cut sales force

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. will lay off hundreds of U.S. sales representatives between now and July 1 as it prepares for the loss of patent protection on two of its best-selling drugs.

The Indianapolis-based drugmaker said Thursday that the layoffs would number “fewer than 1,000,” with fewer than 20 of those occurring in Indiana.

Lilly’s bestselling drug, the antidepressant Cymbalta, will see its U.S. patent expire at the end of this year. That means the nearly $4 billion in annual U.S. sales of Cymbalta will quickly shift to cheaper generic copies.

Then in March 2014, the U.S. patent on Evista, an osteoporosis drug, will expire, evaporating about $700 million in U.S. sales of that drug.

“We’re just planning and expecting to lose that revenue and have had to make some changes in accordance with that,” said Lilly spokesman Scott MacGregor. He declined to disclose the total size of Lilly’s U.S. sales force, citing competitive reasons.

In addition to those sales losses, Lilly officials told a meeting of its sales professionals in Dallas on Wednesday that they are designing new ways to interact with doctors and hospitals that no longer require as many sales people.

“We’ve been on a journey over the last several years to really change the experience that we have with our customers,” MacGregor added.

Lilly will not reduce its sales force for its cancer drugs and will actually add sales personnel in its diabetes division, to support the launch of two new drugs.

Lilly employs a total of 17,000 workers in the U.S., 11,000 of which are located in Indiana.

Other parts of Lilly’s business continue to grow, offsetting the impact of the patent expirations on Cymbalta and Evista. But Wall Street analysts still expect Lilly’s overall revenue to fall from $22.6 billion last year to as low as $20 billion next year.

Lilly’s revenue already declined from an all-time high of $24.3 billion in 2011, after the patent expirations of its blockbuster cancer drug Gemzar in 2010 and its blockbuster antipsychotic Zyprexa in 2011. Lilly has been furiously trying to launch new drugs to replace the roughly $10 billion it will lose from the patent expiration of these four drugs, but has largely been stymied in that quest so far. 


  • Downsizing
    Here are the statistics on downsizing. There has to be another way. http://www.orgsurvival.com/downsizing-how-well-does-it-work/
  • ???
    All of Lilly's drugs go through extensive clinical trials. To be FDA approved, the benefits of the drug must outweigh the risks. Doctors would be the ones to look at an individual's personal health and determine if the drug would have more negative effects than positive. This Lilly "scandal" you speak of is your own personal experience. You should be questioning your doctor, not the entire Lilly corporation.
  • Can you Spell
    LiLLy is spelled LILLY not LiLy dummy
  • Hmmmm
    At least when you buy drugs from the pusher on the corner, you get what you pay for. With Lily, you get a lot more than you pay for in the form of side effects that can kill. I wonder what kind of scum can peddle this garbage day in and day out and look themselves in the mirror. I wonder if the Aurora and Newtown shooters were on Lily pharmaceuticals. So many questions, so few answers from Indiana's shameless pusher men and women at Eli Lily.
  • That explains it
    "Wall Street analysts still expect Lilly’s overall revenue to fall from $22.6 billion last year to as low as $20 billion next year." And so the stock price went up again today...
  • Sales reps and Zyprexa
    Remember the Zyprexa scandal. The Eli Lilly company made an astounding $67 BILLION on Zyprexa that they PUSHED on the elderly and underage children (*Viva Zyprexa* Lilly sales rep slogan) with wanton disregard for the side effects *FIVE at FIVE* The Zyprexa antipsychotic drug,whose side effects can include weight gain and diabetes, was sold to Veterans,children in foster care, elderly in nursing homes. *Five at Five* was the Zyprexa sales rep slogan, meaning *5mg dispensed at 5pm would keep patients quiet*. *Tell the truth don't be afraid*-- Daniel Haszard FMI zyprexa-victims.com

    Post a comment to this story

    We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
    You are legally responsible for what you post and your anonymity is not guaranteed.
    Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
    No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
    We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

    Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

    Sponsored by

    facebook - twitter on Facebook & Twitter

    Follow on TwitterFollow IBJ on Facebook:
    Follow on TwitterFollow IBJ's Tweets on these topics:
    thisissue1-092914.jpg 092914

    Subscribe to IBJ